Physician profile
Dida K Ganjoo
NPI 1265451470
$2,045.46
in general payments reported to CMS, 2019-2025
14 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $401 · 2021: $338 · 2022: $362 · 2023: $250 · 2024: $171 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,001.76 | 2019-2023 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $201.45 | 2020 | |
| Abbvie INC. | $193.80 | 2021-2024 | |
| Alkermes, INC. | $153.26 | 2019-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $126.43 | 2019-2025 | Invega Sustenna |
| Allergan, INC. | $124.72 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $47.29 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $43.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.02 | 2023-2024 | Uzedy |
| Corium, LLC | $36.22 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.81 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $17.65 | 2022 | |
| Almatica Pharma LLC | $17.23 | 2022 | |
| Sandoz INC. | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dida Ganjoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.